Semax (ACTH Fragment Peptide)

Where This Line of Research Started

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

The behavioural interest in this sequence predates Semax by two decades. Dornbush and colleagues published on ACTH 4-10 and short-term memory in 1976, and Sandman and colleagues on MSH/ACTH 4-10 and measures of attention in 1977.

Key facts

Dornbush 1976
Pharmacol Biochem Behav (PMID 189333)
Sandman 1977
J Clin Endocrinol Metab (PMID 192754)
Fragment studied
ACTH(4-10) itself, not an analogue
Domains examined
Short-term memory, attention
Why a fragment
Separating behaviour from steroid release
Semax came later
As a stabilised analogue

Why anyone tested a fragment of a stress hormone

ACTH's main job is stimulating adrenal steroid release. Observations that it also affected behaviour raised an obvious question: was that a consequence of the steroids, or a direct effect? Testing a fragment too short to drive adrenal stimulation was the way to separate the two, which is why attention turned to residues 4 to 10 specifically.

What the fragment offered

A sequence retaining whatever was behaviourally active while lacking the portions required for the endocrine effect. If a fragment produced behavioural changes without the hormonal ones, the behavioural effect could not be attributed to steroid release. That is a clean experimental logic and it is why this particular fragment became a research object.

Research material referenced

Semax 10mg, third-party HPLC tested

Buy Semax · £24.99

What was measured

Dornbush and colleagues examined short-term memory in 1976. Sandman and colleagues examined behavioural and physiological measures of attention in 1977, publishing in the Journal of Clinical Endocrinology and Metabolism. Attention and memory are the two domains this literature has concerned itself with ever since.

Why the research did not simply continue

Native ACTH(4-10) is a short unmodified peptide with no protection against peptidases, so its duration is very limited. A fragment that is interesting but degrades almost immediately is difficult to develop further, and that practical obstacle is what later analogue design set out to address.

How Semax relates to that history

Semax retains positions 4 to 7 of the fragment and replaces what followed with Pro-Gly-Pro, a motif chosen for peptidase resistance. It is a response to the durability problem rather than a new pharmacological idea; the question it was built to pursue is the one the 1970s work posed.

How to weigh 1970s behavioural data

Cautiously. Studies from that period generally involved small numbers, and reporting standards for randomisation, blinding and pre-specified endpoints were considerably looser than current expectations. They establish that a question was asked seriously and found interesting; they do not carry the evidential weight a modern trial would.

Frequently asked questions

Why study a fragment rather than ACTH itself?

To separate behavioural effects from adrenal steroid release. A fragment too short to drive the endocrine effect isolates the question.

What did the 1970s studies examine?

Short-term memory (Dornbush 1976) and behavioural and physiological measures of attention (Sandman 1977).

Why did Semax follow?

Native ACTH(4-10) degrades rapidly. Semax replaces positions 8 to 10 with Pro-Gly-Pro, a peptidase-resistant motif.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More Semax (ACTH Fragment Peptide) articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.